Gum disease (periodontitis) is one of the most prevalent chronic health conditions globally — yet it often goes undetected until it’s advanced. Standard non-surgical periodontal therapy (NSPT) helps remove plaque and tartar buildup. But what if oral care could do more than just clean?
Enter BLIS M18™, a precision probiotic with targeted action against oral pathogens. Unlike generic probiotics, BLIS M18™ is a native strain of Streptococcus salivarius that’s been clinically studied to shift the oral microbiome — where gum disease starts.
New Study Confirms: BLIS M18™ Supports Gum Health at a Microbiological Level
In a double-blind, placebo-controlled clinical trial conducted by Wei-Ju Chen et al., BLIS M18™ was shown to deliver statistically significant improvements across three key oral health metrics:
- Reduced pocket depth — a primary clinical indicator of periodontal disease
- Lower bleeding on probing and plaque index
- Sustained microbiome modulation — even after stopping treatment
Why This Matters for Innovation Teams, Product Developers & R&D Leaders
As the global market for oral probiotics grows (CAGR 7%+), manufacturers are looking for clinically validated, IP-protected ingredients that meet rising consumer expectations for efficacy, transparency, and innovation.
BLIS M18™ offers:
- Clinically supported claims for gum health and microbiome balance
- Precision formulation for targeted efficacy
- Compatibility with various delivery formats (e.g., lozenges, powders, strips)
And because BLIS M18™ is strain-specific and studied in human trials, it provides credible differentiation in a crowded market — exactly what formulators and brand managers need to stand out.
➡️ Curious how BLIS M18™ works – and what this could mean for your product development or clinical approach?
📄 Download the full whitepaper for all the data, charts, and implications
